StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.39 | $0.40 | +3.01% | 0.3M |
| 05-12 | $0.41 | $0.40 | -2.71% | 0.2M |
| 05-13 | $0.39 | $0.41 | +4.87% | 0.2M |
| 05-14 | $0.41 | $0.41 | -0.65% | 0.3M |
| 05-15 | $0.41 | $0.40 | -1.95% | 0.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $56.33K | $431.61K | $600.31K | $10.26K |
Operating Income | $-3.51M | $-42.59M | $-13.09M | $-8.73M |
Net Income | $-3.40M | $-41.51M | $-13.39M | $-6.72M |
EPS (Diluted) | $-0.08 | $-2.70 | $-0.94 | $-0.83 |
Total Assets | $80.66M | $84.18M | $104.83M | $104.29M |
Total Liabilities | $13.84M | $14.06M | $22.16M | $26.43M |
Cash & Equivalents | $3.54M | $6.66M | $355.69K | $15.39K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 40.63M | 40.63M | 23.13M | 16.13M |
No sell-side coverage available for SCNX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.